This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Products from multiple soldto's are in cart. Only products from single soldto is allowed in cart.
No Items In Cart
On November 14, World Diabetes Day will be observed around the globe. Diabetes is a growing issue, with more than 415 million adults living with the disease, a number that is expected to increase to 642 million – or 1 in 10 adults – by 2040.
World Diabetes Day asks that we keep an “Eye on Diabetes” and encourages early testing and diagnosis, which can help reduce complications associated with this growing problem.
Consider the following facts from the International Diabetes Federation (IDF):
◾One in two adults with diabetes is undiagnosed
◾More than 5 million people died from diabetes in 2015
◾Up to 70 percent of Type 2 diabetes cases can be prevented or delayed by adopting a healthier lifestyle
◾More than 12 percent of the total global expenditure on health care is currently spent on adults with diabetes, with the majority of countries spending 5-20 percent of their health care budgets
At West, we’ve been working for more than 90 years to meet the needs of patients dealing with health issues. In fact, our proprietary elastomer sheeting is used in nearly all insulin cartridge delivery and administration products. The sheeting is used in conjunction with a specialized seal to help ensure that insulin is kept sterile, stable and free of any contaminants. It is also a critical functional part of the cartridge in an insulin pen system.
To help meet the rising demand for high-quality insulin sheeting and seals, West is building a new facility in Waterford, Ireland. This unique facility will serve as a center of excellence for the sophisticated manufacturing processes required to meet the needs of the insulin market. The plant will be critical in addressing increased demand for injectable drugs that require high-quality products created using advance manufacturing techniques – including insulin sheeting, seals and cartridge components – and provides dual sourcing of this important piece of the diabetes therapeutic regimen.
It is our hope that by working closely with global customers to meet the needs of patients, we can help create a healthier world through awareness, prevention and treatment of this growing problem.
Learn more about World Diabetes Day here.
IDF Diabetes Atlas 7th edition www.idf.org/diabetesatlas
Take an in-depth look at the science behind containment & delivery of injectable medicines in the West Knowledge Center.
In 2017, West employees have worked diligently to help the communities in which we live and work. Through West without Borders, West's employee-led giving program, employees have raised more than $3 million for a variety of charities around the world.
Cartridge-based administration using injection device systems has dominated the insulin market for many years. In 2011, the insulin market for cartridge-based container closure systems was at an estimated 1 billion units. Additional applications for cartridge-based container systems include dental, at more than 450 million units per year, and therapies such as human growth hormone, interferon and epinephrine. In fact, thanks to lower production costs when compared to vial and syringe systems, cartridge-based delivery has found a widespread and growing market.
The rise in type 2 diabetes has sparked a variety of treatment options, including glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1s are a class of injected drugs (additional oral options are currently in development) that “mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin.”<sup>1</sup> Commonly used when oral treatment alone is not enough, the benefits of GLP-1s include a reduction of glucagon and glycosylated haemoglobin (HbA1c), weight loss and a low risk of hypoglycemia.<sup>2</sup>
When left untreated, diabetes eventually can lead to a variety of issues for patients, including complications such as stroke, blindness and heart and/or kidney disease. In addition, adherence to painful or inconvenient injection treatments can be difficult for patients, with as many at 57% of Type 1 and Type 2 diabetes patients admitting to intentionally skipping injections.<sup>1</sup>
<p>There have been many innovations over the past century since it was first shown that insulin injections could help control chronic diabetes. Advances in hardware and software have resulted in more accurate blood glucose sensors that work via less invasive means and insulin pumps that have become smaller and ever more sophisticated. As we discussed in our <a href="/zh-cn/blog/2017/july/growth-in-glp-1-drugs-may-offer-improved-outcomes-to-people-with-type-ii-diabetes">last blog</a> , there are also newer drugs, that when combined with traditional insulin therapy, can help patients better control the blood glucose levels.</p>